CORT
Corcept Therapeutics Incorporated
118.50$
+4.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 1.3% | 1.4% | 1.7% | 1.5% | 1.6% | 1.6% | 1.5% | 1.8% | 2.2% | 1.3% | 1.7% | 1.6% | 1.7% | |
| 98.7% | 98.6% | 98.3% | 98.5% | 98.4% | 98.4% | 98.5% | 98.2% | 97.8% | 98.7% | 98.3% | 98.4% | 98.3% | |
| 36.8% | 40.4% | 39.9% | 35.9% | 32.5% | 38.6% | 38.6% | 31.1% | 33.2% | 32.1% | 40.2% | 21.0% | 30.6% | |
| 36.6% | 34.8% | 38.3% | 40.9% | 40.4% | 45.8% | 57.7% | 53.4% | 59.7% | 64.4% | 88.1% | 61.3% | 67.0% | |
| 73.4% | 75.2% | 78.2% | 76.7% | 72.9% | 84.5% | 96.3% | 84.5% | 92.9% | 96.5% | 128.3% | 82.3% | 97.5% | |
| 25.2% | 23.4% | 20.1% | 21.7% | 25.5% | 13.9% | 2.2% | 13.7% | 4.9% | 2.2% | -30.1% | 16.1% | 0.8% | |
| – | 2.6% | – | – | – | – | – | – | – | – | – | – | – | |
| 29.4% | 27.2% | 23.8% | 25.4% | 29.0% | 17.6% | 6.1% | 16.3% | 7.3% | 4.9% | -27.1% | 17.9% | 3.2% | |
| 4.1% | 4.0% | 4.9% | 3.7% | 3.1% | 0.7% | -7.0% | -1.8% | -2.1% | -7.1% | -8.2% | -1.1% | -4.2% | |
| 25.4% | 23.2% | 18.9% | 21.7% | 25.6% | 16.7% | 13.1% | 18.1% | 9.5% | 12.0% | -18.9% | 16.5% | 6.6% | |
| 29.7% | 27.6% | 23.9% | 25.6% | 29.3% | 17.8% | 6.4% | 16.5% | 7.6% | 5.1% | -26.8% | 18.3% | 3.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.